Shanghai Henlius Biotech

Henlius has built an integrated biopharmaceutical platform that encompasses the entire product lifecycle, from research and development to manufacturing and commercialization. The firm's business model revolves around the development and sale of monoclonal antibody (mAb) drugs, with a primary focus on oncology and autoimmune diseases. Its revenue is generated from product sales and licensing agreements. A significant milestone was achieved in September 2019 when Henlius completed a US$410 million initial public offering on the Hong Kong Stock Exchange. The company has established a global R&D presence with centers in Shanghai, Taipei, and California, and operates manufacturing facilities in Shanghai that are certified by Chinese, EU, and US GMP standards.

The company's product portfolio includes several commercially launched biologics. HANLIKANG (rituximab) was the first biosimilar developed and approved in China. HANQUYOU (trastuzumab), marketed as HERCESSI™ in the U.S. and Zercepac® in Europe, is a biosimilar used for HER2-positive breast and gastric cancer and is approved in China, the EU, and the U.S. Other key products include HANDAYUAN (adalimumab) for autoimmune diseases, HANBEITAI (bevacizumab) for various cancers, and HANSIZHUANG (serplulimab), the world's first anti-PD-1 mAb for the first-line treatment of extensive-stage small cell lung cancer (SCLC). Henlius is actively advancing a diversified pipeline of approximately 50 molecules, including antibody-drug conjugates (ADCs) and bispecific antibodies, and is exploring immuno-oncology combination therapies centered around its proprietary anti-PD-1 mAb, HANSIZHUANG.